论文部分内容阅读
酶抑制剂一般没有抗菌活性,有富于变化的多样化学结构,显示了微生物产生的次级代谢产物的多样性。如果能够采用正确合理的筛选方法,就有可能从微生物的次级代谢产物中,有目的地发现我们所要的各种生理活性物质。由于抗生素的发现并进入临床使用,使得人们对于感染症的化学疗法取得了很大的进步,但是仍然没有完全解决问题。其原因之一,归结为患者予防功能低劣。再者,对于癌症患者来说,细胞免疫力弱是人所共知的事实。梅泽从这一着眼点出发,设想能够从微生物的次级代谢产物中,寻找到免疫调节物质。考虑到能够与免疫细胞的表面相结合的低分子化合物,高分子的辅酶A等的外源凝集素与淋巴球细胞表面的受纳体相结
Enzyme inhibitors are generally non-antibacterial, have varied and varied chemical structures, and show the diversity of secondary metabolites that microorganisms produce. If we can use the right and reasonable screening methods, it is possible from the secondary metabolites of microorganisms, purposefully found that we want a variety of physiologically active substances. Due to the discovery of antibiotics and their clinical application, great advances have been made in the chemotherapy of infectious diseases, but the problems are still not completely solved. One of the reasons, boiled down to patients with anti-poor function. Furthermore, the weakness of cellular immunity is a well-known fact in cancer patients. Starting from this point of view, Meise envisaged looking for immunomodulatory substances from the secondary metabolites of microorganisms. In consideration of low-molecular compounds capable of binding to the surface of immune cells, the lectin of polymer coenzyme A and the like are bound to the receptors on the surface of lymphocytes